Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
31-GEP Prognostic Assay for Melanoma
Description
The transcript discusses the 31-GEP prognostic assay for melanoma, highlighting the limitations of the traditional AJCC staging system and how the Castle assay aims to provide a more nuanced risk stratification based on gene expression profiles. Current staging inadequacies are illustrated through various patient cases where metastasis does not always align with AJCC classifications. The speaker outlines the development of the Castle assay, identifying its distinct class rankings (Class 1A, 1B, 2A, 2B) based on the expression of specific mRNAs associated with melanoma aggression. Published studies have shown that this assay can predict prognosis more effectively than AJCC alone, particularly in stage 2 patients. The speaker supports the assay's utility in managing patients who are node negative, suggesting significant survival differences based on risk scores. A focus on reducing unnecessary sentinel lymph node biopsies through the assay demonstrates potential cost-saving measures, with further studies confirming its efficacy across various patient cohorts. However, skepticism remains, particularly regarding clinical utility and cost-effectiveness compared to traditional prognostic markers. The discussion highlights the importance of ongoing research and validation in the context of melanoma management, emphasizing a need for both prognostic tests and clinical practices to evolve alongside new findings.
View moreConclusions
- The current AJCC staging for melanoma has limitations that can lead to incorrect prognostications for patient outcomes.
- A significant proportion of melanoma deaths occur in patients who are diagnosed at stages I and II, highlighting the need for improved early detection methods.
- The 31-gene expression profile (GEP) test has been developed as an independent prognostic tool that can effectively stratify melanoma patients based on their risk of recurrence.
- Patients classified into Class 1A by the GEP test exhibit significantly better survival outcomes compared to those in Class 2B.
- The GEP test outperforms traditional staging methods and provides valuable insights in clinical decision-making regarding sentinel lymph node biopsy (SLNB) in melanoma management.
- Results from various studies show that GEP testing can assist in identifying patients with low risk of SLNB positivity, which can help to minimize unnecessary surgical procedures.
- Overall survival and disease-free survival rates are significantly enhanced in patients who are properly stratified using the GEP test, providing a clearer risk assessment compared to conventional staging.
- The use of the GEP test in clinical practice is associated with lower melanoma-specific mortality, demonstrating its potential to improve patient management strategies.
- AJCC v7, (2010) J Clin Oncol
- Morton et al., 2014. N Engl J Med
- Whiteman et al., 2015. J Invest Dermatol
- Shaikh et al., 2016. J Natl Cancer Inst
- Long et al., 2017. Ann Oncol
- Joseph et al., 2018. J Clin Oncol (ASCO abstract)
- Lyle et al., 2014. J Clin Oncol (ASCO abstract)
- Menzies et al., 2014. PLoS One
- Nishino et al., 2014. J Immunother Cancer
- Steinman et al., 2014. J Surg Oncol
- Schadendorf et al., 2017. Eur J Cancer
- Kaufman et al., 2015. J Clin Oncol (ASCO abstract)
- Khoja et al., 2016. Br J Cancer
- Ribas et al., 2016. JAMA
- Huang et al., 2017. Nature
- Long et al., 2016 J Clin Oncol
- Robert et al., 2017. J Clin Oncol
- Gerami, Clin Cancer Res 2013
- Gerami et al. Clin Cancer Res 2015
- Gerami et al. JAAD 2015
- Zager et al. BMC Cancer 2018
- Gastman et al. JAAD 2018
- Morton, N Engl J Med, 2006
- Fleming et al. ASCO 2017
- Vetto et al. Future Oncol. 2019
- Whitman et al. JCO Precis Oncol, 2021
- Bailey et al. JCO Precis Oncol. 2023